Investment Analysts’ Recent Ratings Changes for Akcea Therapeutics (AKCA)

Akcea Therapeutics (NASDAQ: AKCA) has recently received a number of price target changes and ratings updates:

  • 9/7/2018 – Akcea Therapeutics was downgraded by analysts at ValuEngine from a “buy” rating to a “hold” rating.
  • 9/2/2018 – Akcea Therapeutics had its “hold” rating reaffirmed by analysts at Cowen Inc.
  • 8/31/2018 – Akcea Therapeutics was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “Akcea Therapeutics, Inc. is a biopharmaceutical company. It focuses on developing and commercializing drugs to treat patients with cardiometabolic diseases caused by lipid disorders in the United States and internationally. The Company’s drug pipeline consists of volanesorsen, AKCEA-APO(a)-LRx, AKCEA-ANGPTL3-LRx and AKCEA-APOCIII-LRx which are in clinical stage. Akcea Therapeutics, Inc. is headquartered in Cambridge, Massachusetts. “
  • 8/28/2018 – Akcea Therapeutics had its price target lowered by analysts at Stifel Nicolaus from $33.00 to $25.00. They now have a “hold” rating on the stock.
  • 8/8/2018 – Akcea Therapeutics was downgraded by analysts at UBS Group AG from a “buy” rating to a “hold” rating.
  • 8/7/2018 – Akcea Therapeutics had its price target raised by analysts at BMO Capital Markets from $38.00 to $40.00. They now have an “outperform” rating on the stock.
  • 8/7/2018 – Akcea Therapeutics had its price target raised by analysts at Wells Fargo & Co from $33.00 to $46.00. They now have an “outperform” rating on the stock.
  • 8/7/2018 – Akcea Therapeutics had its “hold” rating reaffirmed by analysts at Stifel Nicolaus. They now have a $33.00 price target on the stock.

Shares of Akcea Therapeutics stock opened at $24.16 on Monday. The stock has a market capitalization of $2.13 billion, a price-to-earnings ratio of -10.79 and a beta of 0.37. Akcea Therapeutics Inc has a fifty-two week low of $15.20 and a fifty-two week high of $40.75.

Akcea Therapeutics (NASDAQ:AKCA) last issued its quarterly earnings data on Monday, August 6th. The company reported ($0.72) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.04) by $0.32. The business had revenue of $18.30 million during the quarter, compared to the consensus estimate of $14.24 million. Akcea Therapeutics had a negative net margin of 192.97% and a negative return on equity of 58.32%. The company’s revenue was up 221.1% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($0.41) earnings per share. sell-side analysts expect that Akcea Therapeutics Inc will post -2.45 EPS for the current year.

Institutional investors have recently modified their holdings of the business. Quantbot Technologies LP acquired a new position in shares of Akcea Therapeutics in the first quarter worth about $104,000. Cubist Systematic Strategies LLC acquired a new position in shares of Akcea Therapeutics in the first quarter worth about $201,000. Paloma Partners Management Co acquired a new position in shares of Akcea Therapeutics in the second quarter worth about $216,000. Barclays PLC raised its position in shares of Akcea Therapeutics by 375.7% in the first quarter. Barclays PLC now owns 11,312 shares of the company’s stock worth $290,000 after acquiring an additional 8,934 shares during the period. Finally, Bank of America Corp DE raised its position in shares of Akcea Therapeutics by 79.8% in the second quarter. Bank of America Corp DE now owns 12,368 shares of the company’s stock worth $293,000 after acquiring an additional 5,490 shares during the period. Institutional investors and hedge funds own 26.58% of the company’s stock.

Akcea Therapeutics, Inc, a late-stage biopharmaceutical company, focuses on developing and commercializing drugs to treat patients with cardiometabolic diseases caused by lipid disorders in the United States and internationally. It develops Volanesorsen, which has completed Phase 3 clinical study for the treatment of familial chylomicronemia syndrome; and that is in Phase 3 clinical study for the treatment of familial partial lipodystrophy.

Featured Story: Discover Your Risk Tolerance

Receive News & Ratings for Akcea Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akcea Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply